ACE

Angiotensin-converting enzyme · P12821 · ACE on Sugi Atlas →

150,212 patent compounds predicted against ACE, 86,076 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Quinapril (SCHEMBL15813)	1.00	16/20
Quinapril (SCHEMBL41404)	0.98	16/20
Quinapril (SCHEMBL153436)	0.98	16/20
Moexipril (SCHEMBL34030)	1.00	15/20
Quinaprilat (SCHEMBL113237)	1.00	15/20
Moexipril (SCHEMBL40877)	0.98	15/20
Spirapril (SCHEMBL17202)	0.83	15/20
Enalapril (SCHEMBL18)	1.00	14/20
Enalapril (SCHEMBL97)	1.00	14/20
Enalapril (SCHEMBL9)	0.91	14/20
Enalapril (SCHEMBL10)	0.91	14/20
Trandolaprilat (SCHEMBL156829)	0.82	14/20
Trandolaprilat (SCHEMBL197063)	0.82	14/20
Fumaric Acid (SCHEMBL194895)	0.72	14/20
Imidapril (SCHEMBL34098)	1.00	13/20
Imidapril (SCHEMBL34099)	1.00	13/20
Enalaprilat Anhydrous (SCHEMBL37289)	1.00	13/20
Imidapril (SCHEMBL136722)	0.98	13/20
Enalaprilat Anhydrous (SCHEMBL37288)	0.98	13/20
Cilazapril (SCHEMBL24962)	0.76	13/20

Clinical trials — most relevant to ACE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Telmisartan for Treatment of COVID-19 Patients	PHASE4	COMPLETED
Stopping ACE-inhibitors in COVID-19	PHASE4	COMPLETED
Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension	PHASE4	COMPLETED
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension	PHASE4	COMPLETED
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers	PHASE4	COMPLETED
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19	PHASE2/PHASE3	UNKNOWN
Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis	PHASE3	COMPLETED
The COVID-RASi Trial (COVID-19)	PHASE3	COMPLETED
ACE Inhibition and Novel Cardiovascular Risk Factors	PHASE2	COMPLETED
Use of Angiotensin-(1-7) in COVID-19	PHASE1/PHASE2	COMPLETED
TXA127 for the Treatment of Severe COVID-19	PHASE2	COMPLETED
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19	PHASE2	COMPLETED
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers	PHASE1	COMPLETED
RAS and Coagulopathy in COVID19	EARLY_PHASE1	COMPLETED
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19	nan	UNKNOWN
Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19	nan	UNKNOWN
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome	nan	UNKNOWN
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans	nan	COMPLETED
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)	nan	COMPLETED
Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults	nan	COMPLETED
Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19	nan	UNKNOWN
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker	nan	UNKNOWN
Prognositc Factors in COVID-19 Patients Complicated With Hypertension	nan	WITHDRAWN
Residual Renal Function Preservation in Peritoneal Dialysis Patients	nan	UNKNOWN
Estrogen Therapy in Non-severe COVID-19 Patients	nan	UNKNOWN
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).	nan	COMPLETED
The Effect of RAAS Blockers on ACE2 Levels	nan	COMPLETED
Impact of the Genetic Polymorphism on COVID-19 in Egypt	nan	UNKNOWN
CMR Findings in COVID-19 Patients Presenting With Myocardial Infarction	nan	UNKNOWN
Host Response Mediators in Coronavirus (COVID-19) Infection	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ACE binder may also engage these)

Protein	Name	Similarity
Q9GLN7	—	1.000	Q9GLN7 →
F1RRW5	—	1.000	F1RRW5 →
P12820	—	1.000	P12820 →
P12822	—	1.000	P12822 →
P09470	—	0.999	P09470 →
P47820	—	0.998	P47820 →
Q50JE5	—	0.997	Q50JE5 →
Q10751	—	0.995	Q10751 →
Q58DD0	—	0.989	Q58DD0 →
ACE2	Angiotensin-converting enzyme 2	0.988	landscape →
Q8R0I0	—	0.988	Q8R0I0 →
Q56H28	—	0.986	Q56H28 →
D0G895	—	0.986	D0G895 →
Q9VLJ6	—	0.984	Q9VLJ6 →
Q10715	—	0.982	Q10715 →
Q6Q4G4	—	0.982	Q6Q4G4 →
Q5RFN1	—	0.981	Q5RFN1 →
O95672	—	0.981	O95672 →
Q5EGZ1	—	0.981	Q5EGZ1 →
Q56NL1	—	0.980	Q56NL1 →
Q9JHL3	—	0.980	Q9JHL3 →
P0DPE2	—	0.980	P0DPE2 →
ECE1	Endothelin-converting enzyme 1	0.979	landscape →
B2RQR8	—	0.978	B2RQR8 →
Q9JMI0	—	0.978	Q9JMI0 →
Q10714	—	0.978	Q10714 →
Q4PZA2	—	0.977	Q4PZA2 →
P41245	—	0.977	P41245 →
Q18673	—	0.976	Q18673 →
F1N476	—	0.976	F1N476 →